For Immediate Release December 3, 2020
Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”),
a pharmaceutical company focused on the research, development and commercialization of
oncology and antiviral drugs, today announced that it has paid off just over $100,000 worth of
convertible notes associated with the Company. Our Board of Directors deemed this action to be
a priority for the Company in order to mitigate dilutive conversions and maximize shareholder
Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are pleased to have paid off this
convertible debt within the required time frame and will continue to work towards our overall goal
of growth from the operational side of the business.” We always have our shareholders best
interests in mind,” he added.
About Sunshine Biopharma’s Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the
ongoing COVID-19 pandemic that has claimed the lives of over 1.4 million people worldwide since
it first appeared in December 2019. There are currently no drugs that can effectively arrest
replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine
Biopharma filed a provisional patent application for several molecules which were designed by
computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of
the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such
molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of
Georgia, College of Pharmacy, the Company is currently advancing the development of SBFMPL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials
on COVID-19 patients.
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date
have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells,
including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine
Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at
McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner
of all patents and intellectual property pertaining to Adva-27a.
Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and
assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially
from those anticipated or expected, including statements related to the amount and timing of expected revenues
statements related to our financial performance, expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company
with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ
materially from those projected in or contemplated by the forward-looking statements due to a number of factors
detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain
growth or achieve profitability based upon many factors including but not limited to general stock market conditions.
Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have
incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines
noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long
term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)
based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted
at this time.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464